ライフサイエンスコーパス: tenofovir

25 cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg, which was taken once per da

26 bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg (the bictegravir group) or c

27 bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg (the bictegravir group) or d

28 with co-formulated emtricitabine 200 mg and tenofovir alafenamide 25 mg (the dolutegravir group), ea

29 ed to once-daily oral fixed-dose combination tenofovir alafenamide 25 mg and emtricitabine 200 mg, an

30 bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg or coformulated dolutegravir

31 bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg, or coformulated dolutegravi

32 n with coformulated emtricitabine 200 mg and tenofovir alafenamide 25 mg.

33 330 with dolutegravir plus emtricitabine and tenofovir alafenamide [dolutegravir group]).

34 l development include novel oral agents (eg, tenofovir alafenamide and islatravir [also known as MK-8

35 egravir co-formulated with emtricitabine and tenofovir alafenamide as a fixed-dose combination is rec

36 t the use of bictegravir, emtricitabine, and tenofovir alafenamide as a safe, well tolerated, and dur

37 data support bictegravir, emtricitabine, and tenofovir alafenamide as a safe, well tolerated, and dur

38 data support bictegravir, emtricitabine, and tenofovir alafenamide as a safe, well tolerated, and dur

39 egravir plus co-formulated emtricitabine and tenofovir alafenamide at week 96.

40 erability of bictegravir, emtricitabine, and tenofovir alafenamide compared with co-formulated dolute

41 erability of bictegravir, emtricitabine, and tenofovir alafenamide compared with dolutegravir plus co

42 contrast, tenofovir disoproxil fumarate and tenofovir alafenamide conferred potentially cardioprotec

43 nt (327 with bictegravir, emtricitabine, and tenofovir alafenamide fixed-dose combination [bictegravi

44 Switching to rilpivirine, emtricitabine, and tenofovir alafenamide from efavirenz, emtricitabine, and

45 Tenofovir alafenamide fumarate (TAF) co-formulated with

46 Tenofovir alafenamide fumarate (TAF) co-formulated with

47 s (HIV) infection are dolutegravir (DTG) and tenofovir alafenamide fumarate (TAF).

48 seven participants in the emtricitabine and tenofovir alafenamide group (0.16 infections per 100 per

49 325 in the dolutegravir, emtricitabine, and tenofovir alafenamide group (difference -1.9%, -7.8 to 3

50 325 in the dolutegravir, emtricitabine, and tenofovir alafenamide group (study 2).

51 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide group and -0.10% (3.39) in the ten

52 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide group and -0.73% (3.21) in the ten

53 er mL in the bictegravir, emtricitabine, and tenofovir alafenamide group and 265 (84%) of 315 in the

54 er mL in the bictegravir, emtricitabine, and tenofovir alafenamide group and 273 (84%) of 325 in the

55 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide group and one (2%) participant in

56 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide group did not receive treatment an

57 pants in the bictegravir, emtricitabine, and tenofovir alafenamide group versus five (2%) of 315 in t

58 f 2694 participants in the emtricitabine and tenofovir alafenamide group vs 49 [2%] of 2693 participa

59 h matched placebo tablets (emtricitabine and tenofovir alafenamide group), or emtricitabine (200 mg)

60 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide group; and bronchitis (six [11%]),

61 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide group; and one (2%) in the tenofov

62 Emtricitabine and tenofovir alafenamide had more favourable effects on bon

63 rmulation of rilpivirine, emtricitabine, and tenofovir alafenamide has recently been approved, and we

64 ofovir disoproxil fumarate to one containing tenofovir alafenamide in participants aged 60 years and

65 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people

66 Tenofovir alafenamide is associated with less renal and

67 onsisting of bictegravir, emtricitabine, and tenofovir alafenamide is recommended for treatment of HI

68 apply these methods to a completed trial of tenofovir alafenamide plus emtricitabine for PrEP.

69 Tenofovir alafenamide shows high antiviral efficacy and

70 Daily emtricitabine and tenofovir alafenamide shows non-inferior efficacy to dai

71 ted an elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide single-tablet regimen for human im

72 tients given bictegravir, emtricitabine, and tenofovir alafenamide than in those given dolutegravir,

73 Non-inferiority of emtricitabine and tenofovir alafenamide to emtricitabine and tenofovir dis

74 contrast, tenofovir disoproxil fumarate and tenofovir alafenamide treatment gave rise to greater pop

75 of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide versus continuing a regimen of boo

76 re prophylaxis (PrEP) with emtricitabine and tenofovir alafenamide versus emtricitabine and tenofovir

77 f 320 in the bictegravir, emtricitabine, and tenofovir alafenamide versus six (2%) of 325 in the dolu

78 nucleotide reverse transcriptase inhibitors, tenofovir alafenamide was associated with more weight ga

79 coformulated bictegravir, emtricitabine, and tenofovir alafenamide was non-inferior to a dolutegravir

80 At week 144, bictegravir, emtricitabine, and tenofovir alafenamide was non-inferior to both dolutegra

81 At week 96, bictegravir, emtricitabine, and tenofovir alafenamide was non-inferior to dolutegravir,

82 0% had completed 96 weeks) emtricitabine and tenofovir alafenamide was non-inferior to emtricitabine

83 Emtricitabine and tenofovir alafenamide was superior to emtricitabine and

84 and either tenofovir disoproxil fumarate or tenofovir alafenamide), with a third regimen (efavirenz

85 enamide, 325 to dolutegravir, emtricitabine, tenofovir alafenamide).

86 dy 2 (327 to bictegravir, emtricitabine, and tenofovir alafenamide, 325 to dolutegravir, emtricitabin

87 r with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, abacavir/dolutegravir/lamivudine,

88 dy 1 (314 to bictegravir, emtricitabine, and tenofovir alafenamide, and 315 to dolutegravir, abacavir

89 1 participants were randomly assigned to the tenofovir alafenamide, emtricitabine, and dolutegravir g

90 Participants in the tenofovir alafenamide, emtricitabine, and dolutegravir g

91 eek 96, 276 (79%) of 351 participants in the tenofovir alafenamide, emtricitabine, and dolutegravir g

92 gain was substantial (7.1 kg [SD 7.4] in the tenofovir alafenamide, emtricitabine, and dolutegravir g

93 he clinically approved antivirals, including tenofovir alafenamide, emtricitabine, sofosbuvir, ledipa

94 tions with the backbone of emtricitabine and tenofovir alafenamide, might provide an advantage to pat

95 1) adults to bictegravir, emtricitabine, and tenofovir alafenamide, or dolutegravir 50 mg given with

96 f resistance to elvitegravir, emtricitabine, tenofovir alafenamide, or tenofovir.

97 us RNA suppression while receiving a TDF- or tenofovir alafenamide-containing regimen.

98 Tenofovir alafenamide-emtricitabine (F/TAF) was recently

99 ty, while tenofovir disoproxil fumarate- and tenofovir alafenamide-treated cells and EMP displayed hi

100 ate (ABC), tenofovir disoproxil fumarate, or tenofovir alafenamide.

101 ce of the antiretroviral drugs lopinavir and tenofovir alafenamide.

102 donors, 9 (0.6%; 95% CI, 0.03% to 1.1%) had tenofovir and emtricitabine.

103 There were ten with resistance to both tenofovir and lamivudine, 8 (80.0%) of whom were prescri

104 400-mg dose, known as EFV400), combined with tenofovir and lamivudine.

105 i-log variability typical of biopsy data for tenofovir and other topical microbicides, results sugges

106 ) had resistance to lamivudine, 128 (54%) to tenofovir, and 219 (92%) to efavirenz.

107 ally, we find that although viruses from the tenofovir arm were 2-fold less infectious, they replicat

108 hymidine analogue mutations, M184V/I and the tenofovir-associated DRMs K65R and K70E/Q/G/N/T accounte

109 tis B virus (HBV) coinfected adults starting tenofovir-based antiretroviral therapy (ART) in Zambia,

110 imPol mutation, D114N, in an HIV+ patient on tenofovir-based ART with mitochondrial toxicity.

111 In the treatment of HIV infections 10 tenofovir-based drug combinations have been marketed, an

112 and other anaerobic bacteria, which depleted tenofovir by metabolism more rapidly than target cells c

113 Cervicovaginal fluid tenofovir concentrations did not differ at day 14 (p=0.1

114 quantified tenofovir disoproxil fumarate and tenofovir concentrations in cervicovaginal fluid, tenofo

115 ng adherence at week 24, the proportion with tenofovir concentrations in the hair reflecting at least

116 is delta virus (HDV) viral loads (VL) during tenofovir-containing antiretroviral therapy among patien

117 tissue, focusing on the antiretroviral drug tenofovir delivered by a vaginal gel.

118 The disposition of tenofovir diphosphate (TFV-DP) and emtricitabine triphos

119 Intracellular tenofovir diphosphate (TFV-DP) concentration measured in

120 etion, and the primary adherence outcome was tenofovir diphosphate (TFV-DP) concentrations >=700 fmol

121 Tenofovir diphosphate (TFV-DP) concentrations in TGW and

122 n differential accumulation of intracellular Tenofovir diphosphate (TFV-DP) in different cell types,

123 Tenofovir diphosphate (TFV-DP) in dried blood spots (DBS

124 Although tenofovir diphosphate (TFV-DP) in dried blood spots (DBS

125 Median tenofovir diphosphate (TFV-DP) levels in peripheral bloo

126 llowing daily oral PrEP (emtricitabine 200mg/tenofovir diphosphate 300mg) among pregnant and postpart

127 idenced by repeatedly high concentrations of tenofovir diphosphate in dried blood spots.

128 rvicovaginal fluid, tenofovir in plasma, and tenofovir diphosphate, the active metabolite, in cervica

129 Tenofovir-diphosphate (TFV-DP) in red blood cells was us

130 ylaxis program for Kenyan women, we detected tenofovir-diphosphate in 61% (125/201) of randomly selec

131 ovir-induced toxicity in vitro and show that tenofovir-diphosphate incorporation by PrimPol is depend

132 Tenofovir-diphosphate was detected more frequently among

133 The active metabolite of tenofovir prodrugs, tenofovir-diphosphate, inhibited the incorporation of dA

134 73, 95% confidence interval [CI] 0.56-0.96), tenofovir disoproxil fumarate (0.68, 95% CI 0.49-0.95),

135 Any plaque was negatively associated with tenofovir disoproxil fumarate (0.71, 95% CI 0.51-0.99).

136 ee-drug regimen of dolutegravir (50 mg) plus tenofovir disoproxil fumarate (300 mg) and emtricitabine

137 namide group), or emtricitabine (200 mg) and tenofovir disoproxil fumarate (300 mg) tablets daily, wi

138 10 mg) daily or continued therapy containing tenofovir disoproxil fumarate (300 mg).

139 similar to that seen with oral emtricitabine/tenofovir disoproxil fumarate (94.0%; 55.1%-99.2%).

140 Nine participants switched from E/C/F/tenofovir disoproxil fumarate (E/C/F/TDF 150/150/200/300

141 Background therapies were emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in P007; abacavi

142 f daily oral co-formulated emtricitabine and tenofovir disoproxil fumarate (FTC/TDF).

143 ir alafenamide (n=2694) or emtricitabine and tenofovir disoproxil fumarate (n=2693).

144 , and tenofovir alafenamide (n=111 [66%]) or tenofovir disoproxil fumarate (n=56 [34%]).

145 among participants receiving efavirenz with tenofovir disoproxil fumarate (p=0.001) but not those re

146 enofovir prodrugs - TAF (TAF-based group) or tenofovir disoproxil fumarate (TDF) (TDF-based group) -

147 a 3-arm randomized, pharmacokinetic study of tenofovir disoproxil fumarate (TDF) 300 mg/emtricitabine

148 y randomized to the efavirenz /emtricitabine/tenofovir disoproxil fumarate (TDF) and dolutegravir/emt

149 Oral tenofovir disoproxil fumarate (TDF) and emtricitabine (F

150 the NAPs REP 2139 or REP 2165 combined with tenofovir disoproxil fumarate (TDF) and pegylated interf

151 ed drug combinations have been marketed, and tenofovir disoproxil fumarate (TDF) and tenofovir alafen

152 In the present study, we show that tenofovir disoproxil fumarate (TDF) and tenofovir alafen

153 ose DOR at 100 mg, lamivudine at 300 mg, and tenofovir disoproxil fumarate (TDF) at 300 mg (DOR/3TC/T

154 Tenofovir disoproxil fumarate (TDF) is one of the nucleo

155 emtricitabine (FTC) resistance and increased tenofovir disoproxil fumarate (TDF) susceptibility.

156 change in participants switching from E/C/F/tenofovir disoproxil fumarate (TDF) to E/C/F/TAF.

157 d, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks ge

158 ravir, cobicistat, emtricitabine (E/C/F) and tenofovir disoproxil fumarate (TDF) who switched to E/C/

159 Replacing tenofovir disoproxil fumarate (TDF) with tenofovir alafe

160 2a for 96 weeks and combination therapy with tenofovir disoproxil fumarate (TDF) would increase hepat

161 ion in persons living with HIV (PLWH) taking tenofovir disoproxil fumarate (TDF).

162 s and hospital admission by use of the NRTIs tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC),

163 PLWH receiving tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)/

164 0 mg; once-daily oral fixed-dose combination tenofovir disoproxil fumarate 300 mg and emtricitabine 2

165 or once-daily oral fixed-dose combination of tenofovir disoproxil fumarate 300 mg, emtricitabine 200

166 ) ritonavir (RTV) or standard of care (SOC) (tenofovir disoproxil fumarate 300 mg, emtricitabine 200

167 AD from the DOR groups (DOR/lamivudine [3TC]/tenofovir disoproxil fumarate [TDF] or DOR [100 mg daily

168 ciated with noncalcified/mixed plaque, while tenofovir disoproxil fumarate and efavirenz were negativ

169 ry of Food and Drug Safety in Korea approved tenofovir disoproxil fumarate and emtricitabine (TDF/FTC

170 disoproxil fumarate monotherapy or combined tenofovir disoproxil fumarate and emtricitabine and whet

171 effect in a context that also includes oral tenofovir disoproxil fumarate and emtricitabine as an op

172 eness of the new product in addition to oral tenofovir disoproxil fumarate and emtricitabine as compa

173 tonavir-boosted atazanavir plus coformulated tenofovir disoproxil fumarate and emtricitabine once a d

174 acquisition, the protective efficacy of oral tenofovir disoproxil fumarate and emtricitabine relies o

175 ent film colour), and lamivudine tablets and tenofovir disoproxil fumarate and emtricitabine tablets

176 Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine was adop

177 ing that they are non-inferior to daily oral tenofovir disoproxil fumarate and emtricitabine.

178 iated with less renal and bone toxicity than tenofovir disoproxil fumarate and might improve the long

179 In contrast, tenofovir disoproxil fumarate and tenofovir alafenamide

180 In contrast, tenofovir disoproxil fumarate and tenofovir alafenamide

181 We quantified tenofovir disoproxil fumarate and tenofovir concentratio

182 -six CHB patients who started treatment with tenofovir disoproxil fumarate at a public hospital in Et

183 d eGFR included traditional risk factors and tenofovir disoproxil fumarate exposure.

184 inferior efficacy to daily emtricitabine and tenofovir disoproxil fumarate for HIV prevention, and th

185 namide was non-inferior to emtricitabine and tenofovir disoproxil fumarate for HIV prevention, as the

186 nofovir alafenamide versus emtricitabine and tenofovir disoproxil fumarate for HIV prevention.

187 and 15 participants in the emtricitabine and tenofovir disoproxil fumarate group (0.34 infections per

188 r alafenamide group and -0.10% (3.39) in the tenofovir disoproxil fumarate group (between-group diffe

189 r alafenamide group and -0.73% (3.21) in the tenofovir disoproxil fumarate group (difference 2.04% [1

190 namide group and one (2%) participant in the tenofovir disoproxil fumarate group had an adverse event

191 h matched placebo tablets (emtricitabine and tenofovir disoproxil fumarate group).

192 fovir alafenamide group; and one (2%) in the tenofovir disoproxil fumarate group).

193 f 2693 participants in the emtricitabine and tenofovir disoproxil fumarate group).

194 our [7%]), and arthralgia (four [7%]) in the tenofovir disoproxil fumarate group.

195 lafenamide was superior to emtricitabine and tenofovir disoproxil fumarate in all six prespecified bo

196 pen-label study of rilpivirine/emtricitabine/tenofovir disoproxil fumarate in ART-naive HIV controlle

197 ty, pharmacokinetics, and acceptability of a tenofovir disoproxil fumarate intravaginal ring used con

198 or the prevention of HIV infection with oral tenofovir disoproxil fumarate monotherapy or combined te

199 reased risk of HIV infection, PrEP with oral tenofovir disoproxil fumarate monotherapy or tenofovir d

200 transcriptase inhibitors: emtricitabine and tenofovir disoproxil fumarate or abacavir and lamivudine

201 ravir combined with emtricitabine and either tenofovir disoproxil fumarate or tenofovir alafenamide),

202 Second, the effectiveness of tenofovir disoproxil fumarate plus emtricitabine varies

203 given a new PrEP agent or oral coformulated tenofovir disoproxil fumarate plus emtricitabine.

204 eived one dose of study drug and were on the tenofovir disoproxil fumarate regimen before screening w

205 12 were assigned to receive the tenofovir disoproxil fumarate ring and five were assigne

206 days 14 and 28 compared with baseline in the tenofovir disoproxil fumarate ring group but not the pla

207 Two participants in the tenofovir disoproxil fumarate ring group completed 3 mon

208 grade 2 adverse events were reported in the tenofovir disoproxil fumarate ring group.

209 d finding of ulcerations is specific to this tenofovir disoproxil fumarate ring or generalisable to o

210 V negative were randomly assigned (3:1) to a tenofovir disoproxil fumarate ring or placebo ring.

211 ility of switching from a regimen containing tenofovir disoproxil fumarate to elvitegravir, cobicista

212 nsity of switching from a regimen containing tenofovir disoproxil fumarate to one containing tenofovi

213 d tenofovir alafenamide to emtricitabine and tenofovir disoproxil fumarate was established if the upp

214 afenamide from efavirenz, emtricitabine, and tenofovir disoproxil fumarate was non-inferior in mainta

215 previous use of PrEP with emtricitabine and tenofovir disoproxil fumarate were not excluded.

216 improved renal and bone safety compared with tenofovir disoproxil fumarate when used for HIV treatmen

217 n (efavirenz combined with emtricitabine and tenofovir disoproxil fumarate) previously recommended by

218 de was associated with more weight gain than tenofovir disoproxil fumarate, abacavir, or zidovudine.

219 ses of CAB LA, 6 received oral emtricitabine/tenofovir disoproxil fumarate, and 10 were untreated.

220 retroviral therapy (ART; combined efavirenz, tenofovir disoproxil fumarate, and emtricitabine).

221 citabine, and dolutegravir group, 351 to the tenofovir disoproxil fumarate, emtricitabine, and dolute

222 group, 275 (78%) of 351 participants in the tenofovir disoproxil fumarate, emtricitabine, and dolute

223 and dolutegravir group; 4.3 kg [6.7] in the tenofovir disoproxil fumarate, emtricitabine, and dolute

224 dolutegravir group, and 2.3 kg [7.0] in the tenofovir disoproxil fumarate, emtricitabine, and efavir

225 bine, and dolutegravir group, and 351 to the tenofovir disoproxil fumarate, emtricitabine, and efavir

226 Ten (3%) of 351 participants in the tenofovir disoproxil fumarate, emtricitabine, and efavir

227 wer among infants exposed from conception to tenofovir disoproxil fumarate, emtricitabine, and efavir

228 up, and 258 (74%) of 351 participants in the tenofovir disoproxil fumarate, emtricitabine, and efavir

229 the antiretrovirals abacavir sulphate (ABC), tenofovir disoproxil fumarate, or tenofovir alafenamide.

230 al ring that releases the tenofovir prodrug, tenofovir disoproxil fumarate, provided 100% protection

231 azanavir/ritonavir, lopinavir/ritonavir, and tenofovir disoproxil fumarate, respectively.

232 cells and EMP had greater TF activity, while tenofovir disoproxil fumarate- and tenofovir alafenamide

233 t the magnitude of benefit of PrEP with oral tenofovir disoproxil fumarate-based therapy to reduce th

234 copies per mL), aged 60 years or older, on a tenofovir disoproxil fumarate-containing regimen and wer

235 oninferior and potentially safer option than tenofovir disoproxil fumarate-emtricitabine (F/TDF) for

236 lights the importance of expanding access to tenofovir disoproxil fumarate-sparing regimens in resour

237 rom pivotal studies using oral emtricitabine-tenofovir disoproxil fumarate.

238 come region of enrollment, hypertension, and tenofovir disoproxil fumarate.

239 osted protease inhibitor, emtricitabine, and tenofovir disoproxil fumarate.

240 n coformulated efavirenz, emtricitabine, and tenofovir disoproxil fumarate.

241 inavir/ritonavir, or efavirenz/emtricitabine/tenofovir disoproxil fumarate.

242 rkers of renal safety than emtricitabine and tenofovir disoproxil fumarate.

243 phylaxis (PrEP) interventions worldwide, yet tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) fo

244 P utilization as the number of people taking tenofovir disoproxil fumarate/emtricitabine for HIV prev

245 ed ART-naive participants were randomized to tenofovir disoproxil fumarate/emtricitabine plus atazana

246 s who lost bone mineral density (BMD) during tenofovir disoproxil fumarate/emtricitabine preexposure

247 tenofovir disoproxil fumarate monotherapy or tenofovir disoproxil fumarate/emtricitabine was associat

248 HIV in Kampala, Uganda, and receiving daily tenofovir disoproxil fumarate/lamivudine were recruited.

249 enrollment, participants received daily oral tenofovir disoproxil fumurate and emtricitabine for HIV

250 e-exposure prophylaxis (PrEP) in the form of tenofovir-disoproxil-fumarate/emtricitabine is being imp

251 Tenofovir disproxil fumarate (TDF) has been shown to aff

252 Under these conditions, tenofovir dramatically increased clearance while atazana

253 avir-boosted darunavir plus raltegravir plus tenofovir-emtricitabine or tenofovir plus lamivudine), a

254 r/emtricitabine + a third agent or switch to tenofovir/emtricitabine (TRULIGHT trial).

255 dolutegravir (MONCAY trial), or to continue tenofovir/emtricitabine + a third agent or switch to ten

256 Both participants initiated PrEP with tenofovir/emtricitabine during very early Fiebig stage I

257 HIV preexposure prophylaxis (PrEP) with oral tenofovir/emtricitabine is an effective means of decreas

258 pies/mL) in individuals prescribed primarily tenofovir/emtricitabine/efavirenz in rural KwaZulu-Natal

259 Dual-class PDR to a mainly tenofovir/emtricitabine/efavirenz regimen was associated

260 0.91-2.13), mostly on fixed-dose combination tenofovir/emtricitabine/efavirenz, presence of both nonn

261 ecommended for children aged 2-17 years, and tenofovir for those aged 12-18 years, a conservative app

262 Analysis here is for a tenofovir gel, but this approach offers promise for appl

263 erence up to 72 weeks, and concentrations of tenofovir in hair samples from individuals reporting HIV

264 ovir concentrations in cervicovaginal fluid, tenofovir in plasma, and tenofovir diphosphate, the acti

265 nt, indicating that PrimPol protects against tenofovir-induced mitochondrial toxicity.

266 We established a possible role of PrimPol in tenofovir-induced toxicity in vitro and show that tenofo

267 h perspective, the benefits of transition to tenofovir, lamivudine, and dolutegravir for all substant

268 in all people on ART, including switching to tenofovir, lamivudine, and dolutegravir in those current

269 to be averted with use of a policy in which tenofovir, lamivudine, and dolutegravir is used in all p

270 er sustained topical release formulations of tenofovir or its prodrugs.

271 Pilot studies showed lower tenofovir plasma concentrations during PrEP use among tr

272 ned viral failure on first-line therapy with tenofovir plus a cytosine analogue (lamivudine or emtric

273 r-boosted darunavir, raltegravir, and either tenofovir plus emtricitabine or tenofovir plus lamivudin

274 ovudine plus lamivudine than those including tenofovir plus emtricitabine.

275 raltegravir plus tenofovir-emtricitabine or tenofovir plus lamivudine), and D (best available NRTIs

276 , and either tenofovir plus emtricitabine or tenofovir plus lamivudine), C (ritonavir-boosted darunav

277 An intravaginal ring that releases the tenofovir prodrug, tenofovir disoproxil fumarate, provid

278 eatment with DTG combined with either of two tenofovir prodrugs (TAF and TDF) showed noninferior effi

279 tricitabine (FTC) and DTG plus either of two tenofovir prodrugs - TAF (TAF-based group) or tenofovir

280 Our results suggest that tenofovir prodrugs may be particularly effective as inhi

281 The active metabolite of tenofovir prodrugs, tenofovir-diphosphate, inhibited the

282 Tenofovir reduced HIV incidence by 61% (P = 0.013) in La

283 t-line antiretroviral therapy (ART) based-on tenofovir (TDF) and/or lamivudine (3TC) in a real-world

284 mtricitabine (FTC) resistance, and increased tenofovir (TDF) susceptibility.

285 hepatitis B core antibody (qAnti-HBc) during tenofovir (TDF) treatment and assess their ability to pr

286 dine (3TC), and the nucleotide RTI inhibitor tenofovir (TDF), show efficacy in blocking K103 RT.

287 Tenofovir (TFV) analogues were synthesized by conjugatin

288 Pericoital use of tenofovir (TFV) gel provided protection from HSV-2 acqui

289 ained release profiles of the key metabolite tenofovir (TFV) in skin and plasma over a 50-day period.

290 n seminal plasma (SP) and blood plasma (BP), tenofovir (TFV) in SP and BP, and TFV-diphosphate (dp) i

291 Direct measurement of tenofovir (TFV) in urine could be an objective measure t

292 Tenofovir (TFV) treatment of female reproductive tract (

293 otal plasma concentrations of EVG, TDF, TAF, tenofovir (TFV), and HIV RNA levels were measured at bas

294 em received either prophylactic entecavir or tenofovir therapy.

295 ral pre-exposure prophylaxis (PrEP) based on tenofovir to HIV-negative pregnant and post-partum women

296 Recent reports of tenofovir toxicity in patients taking ART for HIV cannot

297 imPol-knockdown strain was hypersensitive to tenofovir treatment, indicating that PrimPol protects ag

298 mivudine and zidovudine or emtricitabine and tenofovir), versus zidovudine alone.

299 Detectible mucosal tenofovir was lower in non-Lactobacillus women, negative

300 inhibiting low dose infection with the drug tenofovir, which interferes with initial infection, and